Bullish case
$260 to $315
More likely if Omnipod 5 and next-generation products keep growing above 20%, gross margin recovers from Q1 pressure, type 2 diabetes adoption expands, and the market restores a premium growth multiple.
Insulet Corporation research snapshot
PODD AI Stock Analysis
PODD AI stock analysis currently reads Insulet Corporation as a high-quality diabetes device compounder with strong Omnipod revenue growth, recurring pod demand, and expanding international adoption. The setup is not a certain price prediction. At the July 8, 2026 cutoff, the reference quote was $161.55, market capitalization was about $11.19 billion, and the main debate was whether Omnipod growth and operating leverage justify a premium valuation after a sharp drawdown from the 52-week high. This page is informational research and not investment advice.
Current price
$161.55
Market cap
$11.19 billion
AI score
72 / 100
Rating
Quality growth with valuation and device-risk checks
Trend status
Recovering short-term trend below longer-term memory
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
Research quality check
- information Richness
- A-level information richness. Insulet has long public filings, current SEC 10-Q data, investor releases, and broad medical-device coverage, but technical signals vary by provider and must be date-stamped.
- bias Check
- The AI bias risk is consensus anchoring around Omnipod growth. The analysis checks the reverse case: reimbursement pressure, recall execution, competition, long-term multiple compression, and manufacturing scale risk.
- ai Confidence
- High data confidence
- investment Certainty
- Medium. Business quality evidence is strong, but investment certainty is lower because valuation, medical-device recalls, and chart repair can dominate near-term returns.
Quick verdict table
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Insulet sells the Omnipod tubeless insulin delivery platform, with revenue mainly tied to recurring pod consumption and a growing diabetes installed base. | High |
| Moat | The moat comes from tubeless product design, clinical familiarity, switching friction, payer access, manufacturing know-how, and CGM integration partnerships. | Medium-high |
| Management | Management is scaling a global recurring device model while investing in Omnipod 6, type 2 diabetes expansion, manufacturing capacity, and share repurchases. | Medium-high |
| Financial trend | Q1 2026 revenue rose 33.9% to $761.7 million, net income reached $91.1 million, and free cash flow was $89.5 million. | High |
| Valuation | At about 37.8 times trailing EPS and 31.7 times estimated FCF per share, PODD still requires durable double-digit growth and execution discipline. | Medium |
| Technical trend | Short-term price action improved above the 50-day simple moving average, but the stock remains far below its 52-week high and key long-term averages. | Medium |
| Risk level | Risk is moderate to high because device corrections, reimbursement, competition, regulatory scrutiny, and multiple compression can offset strong revenue growth. | Medium-high |
| AI confidence | High for reported financials and business model mapping, medium for technical levels, and lower for future multiple assumptions. | High data confidence |
| Investment certainty | Medium certainty for business quality, but no automatic buy signal because price paid and risk controls matter. | Medium |
PODD AI stock forecast
PODD AI Stock Forecast Scenarios
The PODD AI stock forecast uses scenario ranges from the $161.55 reference quote and a three-year EPS framework. These are conditional ranges, not guaranteed targets, and should be updated after new earnings, device-safety news, or a major technical break.
Base case
$180 to $205
More likely if revenue growth remains strong but valuation settles near a mid-30s earnings multiple while investors wait for evidence on operating leverage, recalls, and 2026 guidance.
Bearish case
$105 to $125
More likely if product corrections hurt trust, reimbursement slows adoption, competitors gain share, or the market compresses PODD toward a lower medical-device multiple.
PODD AI technical analysis
PODD AI Technical Analysis
PODD AI technical analysis uses the July 7 to July 8, 2026 quote area and provider-published moving averages. The short-term chart has bounced from the June low area, but the distance from the 52-week high means trend repair is still incomplete.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $161.55 | MarketWatch reported the July 7, 2026 close at $161.55; use live quotes before trading. |
| Near support | $156 to $158 | This area overlaps the 50-day simple moving average zone reported by multiple technical sources and the recent rebound base. |
| Deeper support | $150 to $153 | A move below this zone would weaken the recovery structure and invite a retest of the 52-week low region. |
| Near resistance | $164 to $170 | The recent rebound has stalled around the low-to-mid $160s; a close above this band would improve short-term momentum. |
| 50-day moving average | $156 to $159 | Sources differed by calculation date, but the stock was slightly above the 50-day simple moving average near the cutoff. |
| 200-day moving average | $246 to $248 | The stock remained well below the 200-day simple moving average, so the longer-term trend still needs repair. |
| Momentum | Neutral to improving | RSI readings around the mid-50s suggest a recovery, not an overextended breakout. |
| Volume | 934,830 shares on July 7, 2026 | MarketWatch reported volume below the 50-day average, so the bounce still needs stronger participation. |
| Volatility | Elevated after 52-week drawdown | The 52-week range of $138.79 to $354.88 shows that position sizing matters even when fundamentals look strong. |
| Invalidation | Close below $150 | A decisive close below the deeper support zone would challenge the recovery thesis and require a fresh review. |
PODD AI trading strategy
PODD AI Trading Strategy Framework
The PODD AI trading strategy is a rules-based research framework, not personalized advice. It pairs business quality with chart confirmation, position sizing, and explicit invalidation levels.
Trend-following setup
Wait for PODD to hold above the $156 to $158 support zone and close above $170 with volume above the recent average before treating the rebound as confirmed.
A close back below $150 or a negative product-safety update should invalidate the setup.
Mean-reversion setup
If PODD retests $150 to $156 without a fundamental thesis break, compare the pullback with Q2 revenue, free cash flow, recall cost updates, and Omnipod adoption data.
Do not average down unless maximum loss, event risk, and holding period are defined before entry.
Fundamental monitor
Track U.S. Omnipod revenue, international Omnipod growth, gross margin recovery, R&D pipeline timing, payer access, and medical-device correction disclosures.
Reduce confidence if revenue growth stays strong but free cash flow, gross margin, or product trust deteriorates.
Investment research summary
Four-master Research Compression
Business essence
Customers pay Insulet for a tubeless insulin delivery platform that reduces friction versus daily injections or tubed pumps while creating recurring pod demand.
Moat
The moat is strongest where product form factor, patient habits, payer coverage, clinician familiarity, manufacturing scale, and CGM compatibility reinforce each other.
Munger risk inversion
The thesis fails if device corrections damage trust, reimbursement becomes tighter, Tandem or Medtronic regain pump momentum, or growth investors refuse the valuation multiple.
Management
Management has executed high revenue growth and positive free cash flow, but must prove that repurchases, pipeline spending, and capacity expansion create per-share value.
Industry trend
Diabetes device adoption remains a long-duration health-care trend, especially automated insulin delivery and type 2 diabetes use cases, but the field is regulated and competitive.
Valuation and margin of safety
The current price is far below the 52-week high, yet valuation still prices in years of growth. Margin of safety depends on sustained earnings growth, not just a lower stock price.
Source-backed data
PODD Data Table
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| PODD price | $161.55 close on July 7, 2026 | MarketWatch PODD quote | July 8, 2026 |
| Market cap and shares | $11.19 billion market cap, 69.26 million shares outstanding | MarketWatch key data | July 8, 2026 |
| Q1 2026 revenue | $761.7 million, up 33.9% year over year | Insulet Q1 2026 results | July 8, 2026 |
| Q1 2026 net income | $91.1 million, or $1.30 diluted EPS | SEC Form 10-Q for quarter ended March 31, 2026 | July 8, 2026 |
| Q1 2026 free cash flow | $89.5 million | SEC Form 10-Q for quarter ended March 31, 2026 | July 8, 2026 |
| Cash and total debt | $480.4 million cash and equivalents, $948.1 million total debt | SEC Form 10-Q for quarter ended March 31, 2026 | July 8, 2026 |
| Full-year 2025 revenue | $2.7 billion, up 30.7% | Insulet FY2025 results | July 8, 2026 |
| 2026 revenue guidance | Total revenue growth guidance of 22% to 24% | Insulet Q1 2026 results | July 8, 2026 |
| Technical moving averages | 50-day SMA near $156 to $159, 200-day SMA near $246 to $248 | StockAnalysis and TipRanks technical snapshots | July 8, 2026 |
| Industry position | Omnipod franchise cited as a leading patch pump position in insulin pump competition | Global Market Insights insulin pump market report | July 8, 2026 |
Frequently Asked Questions
Compare ABT AI stock analysisRead BSX AI stock forecastExplore the AI Stock PickerBuild an AI trading strategy
This PODD AI stock analysis is an informational research tool. It is not investment advice, a recommendation, or a promise of future performance. Forecast scenarios are based on available public data as of July 8, 2026 and can be wrong if Insulet results, product safety, reimbursement, competition, valuation multiples, or market conditions change.